News

Novozymes buys Iogen’s enzymes
Enlarge image

BusinessDenmark

Novozymes buys Iogen’s enzymes

01.02.2013 - With a €50m acquisition Novozymes puts a foot in the pulp & paper, textile, grain-processing and animal feed industries

On January 31st, the Danish enzyme specialist annouced that it will acquire the industrial enzyme business of Canadian cellulosic ethanol specialist Iogen Corporation for €50m. Earn-out payments of up to additional €10m could add to the sum. With the deal Novozymes bags the entire product portfolio of Iogen Bio-Products, including products in development, production sites and IP.

Iogen Bio-Products produces fibre modifying enzymes, such as pulp bleaching enzymes for the pulp and paper branch, fibre processing biocatalysts for textile sector, cellulases and hemicellulases fort he grain-processing and enzymes fort he animal feed industries. Closing of the take-over is expected in February 2013. With the deal Novozymes strenghtens its market position in industrial biotech which complements its already strong position in the cellulosic bioethanol segment that is expanded with aquisitions and collaborations.

© eurobiotechnews.eu/tg 

http://www.european-biotechnology-news.com/news/news/2013-01/novozymes-buys-iogens-enzymes.html

BusinessBelgiumSpain

31.07.2015 Spanish business developer Genetrix has sold its clinical stage cell therapy development subsidiary Coretherapix to Belgian TiGenix in a deal worth up to €267m.

BusinessUKSwitzerland

29.07.2015 Newly founded Mereo BioPharma has acquired three mid-stage clinical assets from Novartis. In turn, the Swiss pharma concern will hold a stake in the UK company. Other investors are also on board.

M&AIreland

28.07.2015 Irish Allergan is bolstering its product pipeline with a takeover of CNS specialist Naurex. At the same time, the company is divesting its global generics business to Teva.

Public marketGermanyFranceBelgiumFinlandDenmarkUK

24.07.2015 Biotech companies across Europe continue to raise cash on the public markets, generating €3bn in total financing proceedings in the first half of 2015. Compared to 2014, this is almost twice as much.

FinanceFrance

23.07.2015 US money keeps flowing into Europe's biotechs. As the race for the peanut allergy market heats up, NASDAQ listed French biotech DBV has announced the successful closing of US$281m (€256m) share offering for its allergy products.

BioplasticsFrance

21.07.2015 French biotech Deinove has launched a R&D programme to produce the versatile chemical intermediate muconic acid by using a designer variant of the Deinococcus bacteria.

BusinessFrance

16.07.2015 Sanofi has announced plans to restructure its business in five standalone global business units starting in January 2016. The goal is to promote growth and help the company launch a catalogue of new drugs over the next five years.

R&DUK

15.07.2015 GlaxoSmithKline (GSK) has become the first drugmaker to join the Francis Crick Institute. It is a consortium made up of six scientific and academic institutes to conduct research and drug development in the UK. The new institute is set to become a world-leading centre of biomedical research and innovation.

FundingUK

13.07.2015 UK drug developer ReNeuron has pulled in £68.4m (€96m) for its cell therapy pipeline for stroke and blindness treatments. Biotech guru Neil Woodford increases his fund’s stake in ReNeuron.

BusinessSweden

10.07.2015 Karolinska Development has slashed the reported value of its portfolio by almost half by revising its valuation model for early stage companies and divesting its shares in pain med maker Pharmanest.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.02 SEK100.00%
  • BIOTIE THERAPEUTICS (FI)0.23 EUR43.75%
  • DIAXONHIT (F)0.79 EUR14.49%

FLOP

  • ZELTIA (E)3.69 EUR-8.44%
  • SWEDISH ORPHAN BIOVITRUM (S)13.05 USD-6.12%
  • ALMIRALL (E)17.75 EUR-5.84%

TOP

  • CHRONTECH PHARMA (S)0.02 SEK100.0%
  • IXICO (UK)34.00 GBP44.7%
  • BIOTIE THERAPEUTICS (FI)0.23 EUR43.8%

FLOP

  • BIOTEST (D)25.52 EUR-64.1%
  • BIOTECH PHARMACON (N)9.45 NOK-44.7%
  • TRANSGENE (F)2.87 EUR-23.5%

TOP

  • ADOCIA (F)86.78 EUR577.4%
  • FORMYCON (D)28.39 EUR323.1%
  • DBV TECHNOLOGIES (F)79.24 EUR317.5%

FLOP

  • CHRONTECH PHARMA (S)0.02 SEK-77.8%
  • NEUROVIVE PHARMACEUTICAL AB (S)22.10 SEK-70.6%
  • NEOVACS (F)1.02 EUR-68.6%

No liability assumed, Date: 31.07.2015